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Kaposi’s sarcoma-associated herpesvirus (KSHV; human herpesvirus 8) is a human her-
pesvirus, classiﬁed as a gamma-herpesvirus. KSHV is detected in Kaposi’s sarcoma (KS),
primary effusion lymphoma (PEL), and some cases of multicentric Castleman’s disease
(MCD). Similar to other herpes viruses, there are two phases of infection, latent and lytic. In
KSHV-associated malignancies such as KS and PEL, KSHV latently infects almost all tumor
cells. Quantitative PCR analysis revealed that each tumor cell contains one copy of KSHV
in KS lesions.The oncogenesis by KSHV has remained unclear. Latency-associated nuclear
antigen (LANA)-1 plays an important role in the pathogenesis of KSHV-associatedmalignan-
cies through inhibition of apoptosis and maintenance of latency. Because all KSHV-infected
cells express LANA-1, LANA-1 immunohistochemistry is a useful tool for diagnosis of KSHV
infection. KSHV encodes some homologs of cellular proteins including cell-cycle regula-
tors, cytokines, and chemokines, such as cyclin D, G-protein-coupled protein, interleukin-6,
and macrophage inﬂammatory protein-1 and -2. These viral proteins mimic or disrupt host
cytokine signals, resulting in microenvironments amenable to tumor growth. Lytic infec-
tion is frequently seen in MCD tissues, suggesting a different pathogenesis from KS and
lymphoma.
Keywords: Kaposi’s sarcoma-associated herpesvirus, HHV-8, latency-associated nuclear antigen, LANA-1, primary
effusion lymphoma
INTRODUCTION
The 1994 discovery of Kaposi’s sarcoma-associated herpesvirus
(KSHV, human herpesvirus 8, HHV-8) in Kaposi’s sarcoma (KS)
tissues had a huge impact, not only in the ﬁeld of virology, but
also on bioscience generally (Chang et al., 1994; Ganem, 2005).
Before the discovery of KSHV, almost all viruses had been identi-
ﬁed using conventional virus isolation methods with cell cultures.
DNA fragments of KSHV were identiﬁed in KS tissues by repre-
sentational difference analysis, which is a subtraction PCR-based
method to purify restriction-endonuclease-digested fragments
present in one population of DNA fragments but not in others
(Chang et al., 1994). Thus, KSHV is the ﬁrst virus whose frag-
ments were identiﬁed directly by the PCR method before any cell
culture methods. In 1996, KSHV-infected cell lines were estab-
lished, based on the fragments’ DNA sequences (Renne et al.,
1996b). Herpesvirus-like particles of this virus were found in lym-
phoma cells by electron microscopic analysis. Finally, KSHV’s full
DNA sequence was determined (Russo et al., 1996). Over the
15-years since the discovery of KSHV, it has been established as
a tumor virus (Ganem, 2005). Some KSHV-encoded genes are
homologous to oncogenes or cell-cycle-associated genes (Russo
et al., 1996); some are transformational genes, able to transform
human cells (Gao et al., 1997; Bais et al., 1998; Lee et al., 1998;
Muralidhar et al., 1998). However, expression of KSHV-encoded
genes is severely restricted; only a few viral genes are expressed
in KSHV-infected cells. The KSHV-encoded latency-associated
nuclear antigen 1 (LANA-1) is the only proteinwhose expression is
stably detected by immunohistochemistry in KSHV-infected cells
(Dupin et al., 1999; Katano et al., 2000b). LANA-1 is a multifunc-
tional protein, but has no full transforming activity. In compari-
son, Epstein–Barr virus (EBV) encodes a full oncogenic protein,
latentmembrane protein-1 (LMP1),which is expressed in a subset
of EBV-latently infected cells (Cohen, 2000). Thus, KSHV onco-
genesis is not simple. Many KSHV-encoded non-transforming
proteins apparently collaborate to establish and maintain onco-
genesis in KSHV-infected cells. In this review, the pathological
aspects of KSHV infection and KSHV-associated diseases are
summarized.
VIRUS AND ITS GENE EXPRESSION
Usually, viral particles are not observed in KS samples by electron
microscope because of the small number of KSHV copies. How-
ever, they can be seen in primary effusion lymphoma (PEL) cell
lines stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA).
A complete viral particle of KSHV, consisting of a capsid and an
envelope (Renne et al., 1996b; Said et al., 1996, 1997; Orenstein
et al., 1997; Ohtsuki et al., 1999), is 150–200 nm in diameter,which
is similar to other human herpes viruses and indistinguishable
from other herpes viruses. The unenveloped capsid is produced in
the host nucleus and is 100 nm in diameter. It contains a central
DNAcore,which appears to have a high electrondensity. The enve-
lope is derived from the inner nuclear membrane, as viral particles
bud into the cytoplasm from the nucleus. The tegument protein
ﬁlls the space between the nucleocapsid and envelope. This feature
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of viral particles is apparently quite similar among herpes viruses,
but related structures forming in infected cells seem to depend on
the type of virus.
The KSHV genome consists of linear, double-stranded DNA
of about 170 kbp (Renne et al., 1996a; Russo et al., 1996). The
KSHV genome consists of a long unique region (LUR) and a ter-
minal repeat (TR) at both termini, which resembles the herpes
virus saimiri structure (Russo et al., 1996). The TRs consist of
801-bp direct repeat units having 84.5%GC content. The number
of repeats in TRs may vary. The LUR is 140.5 kbp and has 53.5%
GC content. KSHV encodes more than 80 viral proteins on LUR.
KSHV also encodes 17 microRNAs (miRNAs), which are derived
by processing from 12 pre-miRNAs (Cai et al., 2005). Kinetics of
KSHV-encoded genes were mainly investigated in KSHV-infected
PEL cell lines stimulated with phorbol ester such as TPA (Sun
et al., 1999). Like other herpesviruses, viral genes were catego-
rized into lytic and latent genes, and also into immediate-early
(IE), early (E), and late (L) genes based on their expressions.
The function of each KSHV-encoded gene was summarized in
the Table 1. Open reading frame 50 (ORF50) is an IE gene
that is a homolog of Rta, a transcriptional activator encoded by
EBV (Lukac et al., 1999; Seaman et al., 1999; Sun et al., 1999;
Zhu et al., 1999). Transcription of ORF50 results in its expres-
sion within 4 h after stimulation by TPA. This expression could
not be blocked by phosphonoacetic acid (a herpesvirus-DNA
polymerase inhibitor) nor cycloheximide (a protein synthesis
inhibitor). Transfection of ORF50 to KSHV-infected cells resulted
in the activation of lytic gene expression (Lukac et al., 1999). Thus,
ORF50 protein is a lytic switch protein. Expression of ORF50 pro-
tein is required for expression of many KSHV-encoded lytic genes
such as K3, and K5 (homologs of the IE gene of BHV-4), viral
interleukin-6 (vIL-6), viral macrophage inﬂammatory proteins
(vMIPs), polyadenylated nuclear RNA (PAN ), vBcl-2, K12, viral
G-protein-coupled receptor (vGPCR), viral dihydrofolate reduc-
tase (vDHFR), DNA replication factors, and thymidylate synthase
(Sarid et al., 1998). ORF50 protein also induces expression of
K8 (K-bZIP, a positional homolog of EBV BZLF1) protein, an
early protein. K8 protein plays a role as transactivation repressor
for ORF50 protein, leading to a negative autoregulation system
during lytic infection (Liao et al., 2003). Late genes, including tegu-
ment proteins, and virion-associated protein are then expressed
(Table 1).
Latent infection is predominant in KSHV infection. KSHV
codes a latency-associated gene cluster includingORF73 (LANA-1,
LNA, or LNA-1), v-cyclin (ORF72), viral FLICE-inhibitory pro-
tein (K13, v-FLIP), Kaposin (K12), and viral-encoded miRNAs.
LANA-1 is always detected as a dot-like staining pattern in KSHV-
infected cells by immunohistochemistry. KSHV-encoded 17 miR-
NAs, which are derived by processing from 12 pre-miRNAs, are
expressed during viral latency (Cai et al., 2005; Samols et al., 2005).
KSHV ONCOGENESIS
The ﬁrst evidence of transformation activity by KSHV came from
a report describing that human umbilical vein endothelial cells
(HUVEC) were transformed and immortalized by KSHV infec-
tion in vitro (Flore et al., 1998). However, such KSHV-infected
Table 1 | Kaposi’s sarcoma-associated herpesvirus genes and their
functions.
Gene Phase Functions
LANA-1 Latent Always express in KSHV-infected cells
Maintain and replicate viral genome
during mitotic division by holding KSHV
episome at chromosome
Bind to p53 and inhibit p53-dependent
apoptosis
Bind to Rb and inhibit Rb-E2F pathway
Bind to GSK-3β, and induce accumulation
of β-catenin
LANA-2 Latent Expressed in only PEL cells, not in KS
cells
Homolog of IRF
Inhibit p53-dependent apoptosis
Kaposin Latent Kaposin A: transformation activity?
Kaposin B, C: associate with cytokine
expression as adaptor protein of MAP
kinase-associated protein kinase 2 (MK2)
v-cyclin Latent Homolog of cyclin D1
Inhibit P27Kip1, and induce cell-cycle to
S-phase
v-FLIP Latent Anti-apoptosis
ORF50 (RTA) Lytic (IE) Lytic switch protein
Transactivator for K8
K1 Lytic Transformation activity
K8 Lytic (early) Transcriptional repressor for RTA
K3, K5 Lytic (IE/early) Down-regulation of MHC class I
expression
vIL-6 Lytic (early) Induce VEGF expression
Induce constitutional activation of Stat3
Disrupt anti-viral function by IFN-α
vIRF-1 Lytic (early) Disrupt IFN signal
Transformation activity?
vMIPs Lytic (early) Bind to chemokine receptors and induce
angiogenesis
vBcl-2 Lytic (early) Inhibit apoptosis
vGPCR Lytic (early) Transformation activity
Bind to IL-8
Induce VEGF expression
K15 Lytic Bind toTRAF family, and induction of
NF-κB activation
HUVEC did not express any KSHV gene, and the immortaliza-
tion by KSHV infection was not conﬁrmed by any other groups
(Gao et al., 2003; Tang et al., 2003). KSHV efﬁciently infects
primary cultures of human endothelial cells in vitro (Sakurada
et al., 2001; Gao et al., 2003). KSHV-infected cells express LANA-
1 within several hours after infection. One week after infection,
a large portion of culture cells will be infected by KSHV and
expressing LANA-1. Interestingly, expression of any lytic proteins
encoded by KSHV is not observed at that time. Latent infec-
tion is dominant in KSHV-infected cells in vivo and in vitro.
Although some KSHV-encoded proteins such as K1 and vGPCR
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are shown to have a transformation activity on mammalian cells,
these transforming proteins are not usually expressed in KSHV-
infected cells (Bais et al., 1998; Lee et al., 1998; Montaner et al.,
2003). However, LANA-1, amajor KSHV-encoded latency protein,
is always expressed in KSHV-infected cells both in vivo and in vitro
(Dupin et al., 1999; Katano et al., 1999b; Kellam et al., 1999).
Moreover, latency is maintained during the presence of KSHV in
the cells. Thus, LANA-1 clearly plays an important role in the
pathogenesis of KSHV infection, and has been shown to be a mul-
tifunctional protein. Probably themost important role of LANA-1
is to establish and maintain the latency in KSHV-infected cells by
tetheringKSHVDNA to host chromosomes (Ballestas et al., 1999).
LANA-1 binds directly to TR sequences of the KSHV genome,
and recruits it to the host chromosome (Figure 1E). The DNA
of KSHV is replicated during host cell divisions using host DNA
replicative machinery (Sakakibara et al., 2004). Thus, daughter
cells inherit KSHV genome without any virus particle. LANA-
1 is also associated with signal transduction in KSHV-infected
cells. LANA-1 binds directly to p53, a major tumor repressor
and anti-apoptotic factor (Friborg et al., 1999). Viral infection
usually induces p53 expression and p53-dependent apoptosis as
self-defense system.Direct interactionwith p53 by LANA-1 results
in inhibition of p53-dependent apoptosis in KSHV-infected cells.
Moreover, LANA-1 stabilizes β-catenin by binding to the nega-
tive regulator GSK-3β, promoting cell-cycle induction by nuclear
accumulation of GSK-3β (Fujimuro et al., 2003). Thus, LANA-
1 plays a central role in the pathogenesis of KSHV infection,
but LANA-1 itself does not have any full transformation activ-
ity. Many other factors besides LANA-1 are required to establish
KSHV oncogenesis.
Another important factor in KSHV oncogenesis is that KSHV
encodes many homologs of human genes. The viral genes of
human gene homologs cooperate to establish suitable growth con-
ditions for KSHV-infected cells. Among them, vIL-6 is the most
important factor for KSHV pathogenesis. vIL-6 induces angiogen-
esis by vascular endothelial cell growth factor (VEGF) expression
(Aoki et al., 1999), and stimulates the constitutive Jak-Stat path-
way through the Stat3 signal, resulting in cell growth (Aoki et al.,
2003). In addition, vIL-6 represses the anti-viral function of inter-
feron by binding to a subunit of human IL-6 receptor and sup-
pressing p21 expression (Chatterjee et al., 2002). KSHV-encoded
vMIP-1, vMIP-2, vBcl-2, vIRF-1, v-cyclin D, and v-FLIP mimic
their human homologs, and work sometimes as inhibitors and
sometimes as mimics, resulting in growth of KSHV-infected cells.
Because almost all these mimics are lytic proteins, their expres-
sion is not usually observed. However, some cytokines may induce
their expression independently to lytic and latent infection as nec-
essary. Thus, KSHV oncogenesis is established by cooperation of
many viral proteins such as LANA-1 and by the mimic, rather
than the primary functions of oncogenetic transformation genes
encoded by the virus.
Recently, miRNA has been shown to affect tumor biology. Sev-
eral KSHVmiRNAswere shown tomodulate host gene expression,
suggesting some roles for miRNA in the pathogenesis of KSHV-
induced malignancies. Thrombospondin 1, a potent inhibitor of
angiogenesis that is reportedly downregulated in KS lesions, is tar-
geted by multiple miRNAs (Samols et al., 2007). The target of
FIGURE 1 | Histological analysis on KSHV-associated diseases. (A)
Nodular stage of KS; HE staining. (B) LANA-1 immunohistochemistry of KS.
(C) Giemsa staining of PEL. (D) LANA-1 immunoﬂuorescence staining in
mitosis of PEL cells. (E) LANA-1 immunostaining of mitosis of PEL cell line,
TY-1.Yellow signals indicate LANA-1. Red is counter staining of chromosome.
(F) HE staining of MCD. (G) LANA-1 immunohistochemistry of MCD.
miR-K5 is Bcl2-associated factor BCLAF1, which promote apop-
tosis (Lei et al., 2010).MiR-K1 targets IκBα, an inhibitor of NF-κB.
NF-κB inhibits the activation of lytic viral promoters. By activat-
ing NF-κB, miR-K1 suppresses viral lytic replication, maintaining
latent infection (Ziegelbauer et al., 2009). So far, miRNAs’ roles in
viral infection and replication remain unclear.
EPIDEMIOLOGY
Serological studies have revealed that KSHV-infected individu-
als are found all over the world. Serum antibody to KSHV is
detectedwith ELISA using lysate of KSHVviral particles or recom-
binant viral proteins as antigens, or immunoﬂuorescence assay
using KSHV-infected cells. The seroprevalence of KSHV infection
differs among regions/countries. Among the general population,
KSHV seropositivity is less than 10% in northern Europe, Amer-
ica, andAsia, 10–30% in theMediterranean region, andmore than
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Table 2 | Kaposi’s sarcoma-associated herpesvirus genotypes.
Genotype Patients, infected persons
A AIDS–KS patients in the US, Europe, Eurasia
B KS patients of African heritage
C Classic KS, iatrogenic, and AIDS–KS in Eurasia, US AIDS–KS,
Taiwan, Korea, China, Middle East
D KS patients of Paciﬁc island
E South American (partial), Brazil Amerindian, Guinea
Amerindian
50% inmost of sub-Saharan Africa (Davis et al., 1997; Kedes et al.,
1997; Chatlynne et al., 1998; Mayama et al., 1998; Rabkin et al.,
1998; Katano et al., 2000a). The homosexual population exhibits
higher positivity (8–25%) than the general population (Grulich
et al., 2005; Casper et al., 2006; Engels et al., 2007). Although
the transmission modes of KSHV have not yet been clariﬁed,
transmission though saliva is likely (Pauk et al., 2000), because
high KSHV copy numbers are detected in saliva of seroposi-
tives. Horizontal transmission through the saliva transmission
is suggested among children in endemic countries, while sex-
ual transmission may be predominant among homosexual men
in non-endemic countries. Organ transplantation can transmit
KSHV (Regamey et al., 1998). Transmission of KSHV through
blood transfusion is controversial. While KSHV seroconversion
was found in US transfusion recipients (Hladik et al., 2006),
later studies found no signiﬁcant association of KSHV infection
between transfusion groups and non-transfusion groups (Cannon
et al., 2009).
Genotypes of KSHV are categorized based on sequences of the
hypervariable regions in itsK1 gene (Meng et al., 1999; Zong et al.,
1999; Biggar et al., 2000; Kazanji et al., 2005; Hayward and Zong,
2007; Kanno et al., 2010). The KSHVK1 genes are classiﬁed into at
ﬁve groups: A, B, C, D, and E (Table 2). Geographical differences
in KSHV genotypes may reﬂect the history of migration of human
populations (Zong et al., 1999). SubtypesA andCwere detected in
Japan and subtype A was seenmore frequently in AIDS-associated
cases than non-AIDS patients (Kanno et al., 2010). There is no cor-
relation between genotype and KSHV-related disease, including
KS, PEL, and multicentric Castleman’s disease (MCD).
KSHV-RELATED DISEASES
Fragments of the KSHV genome have been detected in DNA sam-
ples extracted fromvarious diseases byPCR.However, the only dis-
eases whose associations with KSHV infection are widely accepted
among researchers in this ﬁeld are KS, PEL, and MCD (Table 3).
KSHV is distributed all over theworld, and there aremany individ-
ualswithKSHV infections. Therefore,a lowKSHVtiter,as detected
by PCR, does not mean that a disease is associated with KSHV
infection. Because KSHV LANA-1 is always expressed in KSHV-
infected cells, LANA-1 immunohistochemistry is a powerful and
conﬁrmative tool to detect KSHV-infected cells in pathological
samples, and the association with KSHV infection in diseases
should be examined by LANA-1 immunohistochemistry on tissue
samples.
Table 3 | Kaposi’s sarcoma-associated herpesvirus and diseases.
Usually detected (Conﬁrmed
association in all cases)
Kaposi’s sarcoma (all subtypes),
primary effusion lymphoma
Partially detected (Conﬁrmed
association only in KSHV+ cases)
Multicentric Castleman’s disease
including POEMS (polyneuropathy,
organomegaly, endocrinopathy, M
protein, skin changes) syndrome,
febrile maculopapular skin rash,
hemophagocytic syndrome
Detected in reports, but no
association with KSHV infection
Multiple myeloma, primary pul-
monary hypertension, Bowen
disease, squamous cell carcinoma,
Paget disease, actinic keratosis etc.
PRIMARY KSHV INFECTION
A mass study of immunocompetent children in Egypt, where
KSHV infection is common, suggested that a febrile macu-
lopapular skin rash was associated with primary KSHV infection
(Andreoni et al., 2002). Seroconversion for KSHV was conﬁrmed
in those patients and transmission through saliva was implied by
DNA sequences in saliva.A study of homosexualmenwithoutHIV
infection suggested that diarrhea, fatigue, localized skin rash, and
lymphadenopathy were also symptoms of primary KSHV infec-
tion (Wang et al., 2001). Moreover, active KSHV infection may be
associated with non-malignant illnesses such as fever, cutaneous
rash, and hepatitis after peripheral blood stem cell/bone marrow
transplantation (Luppi et al., 2000).
KAPOSI’S SARCOMA
Kaposi’s sarcoma is most important and common of KSHV-
associated diseases. Four clinical subtypes have been recog-
nized: classic, AIDS-associated, post-transplantational (iatrogenic
or immunodeﬁcient), and African (endemic) subtypes (Antman
and Chang, 2000). These four subtypes of KS are histologically
indistinguishable. In the AIDS–KS subtype, KS occurs only in
homosexualmen.KSoccurs in the skin,oral cavity,gastrointestinal
tract, lung, liver, lymph node, etc. Skin lesions of KS aremost com-
mon; they are clinically classiﬁed as patchy, plaque, and nodular
stages. In the patchy stage, small red ﬂat lesions are observed on the
skin. Histologically, dilated, abnormally shaped blood vessels with
extravasated red blood cells and edema are found in KS lesions.
In the plaque stage, patchy lesions fuse together to form plaque
lesions. Proliferation of the spindle-shaped cells is seen around
vessels in the plaque stage. In the ﬁnal nodular stage, brown nodu-
lar, and elevated lesions are observed. Histologically, proliferation
of spindle cells with slit-like vascular spaces is found (Figure 1A).
Multiple KS lesions in the extremities or face are often complicated
with lymphedema. Pulmonary lesionsmay lead to fatal respiratory
compromise.
Kaposi’s sarcoma should be diagnosed with histology and
immunohistochemistry. Immunohistochemical staining with
anti-LANA-1 antibody shows that the viral protein is expressed in
KS cells, irrespective of clinical type or disease stage (Dupin et al.,
1999; Katano et al., 1999b). Expression of LANA-1 can be seen in
nuclei of KS spindle cells with a speckled pattern (Figure 1B). The
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lymphatic marker, podoplanin (D2-40), is also expressed in KS
cells (Weninger et al., 1999). In addition to histological investiga-
tion, PCR analysis is useful for the KS diagnosis. Because each KS
cell contains about one copy of the KSHV genome, KSHV DNA
fragments are consistently detected by PCR, even in formalin-
ﬁxed parafﬁn-embedded KS tissues (Asahi-Ozaki et al., 2006).
PCR sometimes, but not always, detects KSHV DNA in the sera
of KS patients. Serum antibody to KSHV is usually positive in KS
patients.
Highly active anti-retroviral therapy (HAART) is effective on
KS. Incidence of KS in HIV-infected persons has dramatically
decreased in the HAART era. Regression of KS is often observed
in patients administrated with HAART. In patients with low CD4
counts, KS progresses earlier than in patients with high CD4
counts. These data suggest that KS progression depends on the
host’s immune status (Bower et al., 2009). Recently, patients with
KS were administrated with HAART. Patients with aggressive KS
received a combination therapy of HAART and chemotherapy of
pegylated liposomal doxorubicin (Martin-Carbonero et al., 2008).
Irradiation or surgical resection is also performed for the case
of small skin lesion in addition to HAART. There is no effective
anti-KSHV therapy for KS. Although vaccine is the most effec-
tive method to prevent viral diseases, no vaccine against KSHV is
commercially available at present.
The pathological roles of KSHV in KS have been intensely
investigated for a long time. The origin of KS cells is thought
to be endothelial cells. However, cellular protein expression in
KS cells is very different from those of endothelial cells. Infec-
tion by KSHV induces a dynamic alteration of gene expression
in endothelial cells (Hong et al., 2004; Wang et al., 2004). Analy-
sis via DNA array revealed that endothelial cells reduce expres-
sion of blood vascular genes and induce markers of lymphatic
endothelial cells after KSHV infection in vitro. Thus, KSHV can
affect the expression level of cellular proteins in endothelial cells.
LANA-1 is expressed in the nucleus by almost all KS spindle
shaped cells (Figure 1B), whereas the expression of lytic pro-
teins is limited in KS lesions. Therefore, it is likely that latent
infection by KSHV is important for the pathogenesis of KS.
As described above, LANA-1 plays a central role in the estab-
lishment and maintenance of latency. In addition to LANA-1,
cytokines are important for KS pathogenesis. Some cytokines have
been detected in the sera of KS patients at high levels. It has
been demonstrated that bFGF, IL-6, oncostatin M (OSM), and
tumor necrosis factor (TNF)-alpha are required for growth of
KS cells in vitro (Liu et al., 1997; Faris et al., 1998; Murakami-
Mori et al., 1998). IL-6 is known to be an important growth
factor of KS cells especially in vitro. KSHV-encoded vIL-6 inter-
acts with the receptor of human IL-6, mimics its function par-
tially, and contributes to immune escape mechanism by KS cells
as described above. KSHV-infected cells have several immune
escape mechanisms besides that of vIL-6. K5, a lytic protein of
KSHV, down-regulates MHC class I and co-activation molecules,
enabling productively infected cells to escape both cytotoxic T
cell and NK cell responses (Ishido et al., 2000). In addition,
latently infected cells are also resistant to cytotoxic T cell responses
owing to reduced levels of MHC class I molecules, impaired
antigen processing, and expression of the anti-apoptotic KSHV
ORF-K13/viral FLICE-inhibitory protein (v-FLIP; Thome et al.,
1997).
PRIMARY EFFUSION LYMPHOMA
Primary effusion lymphoma is a rare disease occurring mainly in
immunosuppressed patients, in particularHIV-infected homosex-
ual males (Cesarman et al., 1995; Nador et al., 1996). PEL appears
as lymphomatous effusions occurring in the pleural, abdominal,
or pericardial effusion in the absence of a contiguous tumor mass.
Some patients with PEL secondarily develop solid tumors in adja-
cent structures such as the pleura; these solid tumors have been
termed extracavity PEL (Chadburn et al., 2004). About half of PEL
patients have KS. These tumors always carry KSHV and are com-
monly co-infected by EBV. Histologically, the tumor cells exhibit
various appearances, from large immunoblastic or plasmablas-
tic cells to cells with more anaplastic morphology (Figure 1C).
Nuclei vary from large and round to more irregular in shape, with
prominent nucleoli. The cytoplasm can be abundant and is deeply
basophilicwith vacuoles in occasional cells. Binucleated ormultin-
ucleated cells resembling Reed–Sternberg cells can be seen.Mitotic
ﬁgures are typically numerous. PEL cells are derived from post-
germinal center B-cells (Jenner et al., 2003). Their immunopheno-
types areundetermined, i.e.,CD45 (+),CD138 (+),B-cellmarkers
(−), T cell markers (−); however, their immunoglobulin genes
are clonally rearranged and hypermutated. PEL cells contain high
copy numbers (about 50 copies/cells) of KSHV DNA (Cesarman
et al., 1995; Asahi-Ozaki et al., 2006). PEL cells are sometimes
co-infected with EBV, while others are infected only with KSHV.
However, expressions of LMPs and EBNAs are suppressed in PEL
cells. Several KSHV-infected cell lines have been established from
PEL cells (Carbone et al., 2010). A KSHV+/EBV− cell line, TY-1,
was even established from EBV+ and KSHV+ PEL cases, sug-
gesting that KSHV plays an essential role in the pathogenesis of
PEL (Katano et al., 1999a). Infection by KSHV is predominantly
latent in PEL cells, which has made PEL cell lines the most widely
studied models for KSHV latency. PEL cells express latent genes
coded in the latent cluster in KSHV genome (Figure 1D). How-
ever, it is not easy to detect latent viral protein expressions other
than LANA-1. The expression pattern of KSHV-encoded proteins
is almost the same as KS, except that PEL cell express LANA-2
protein (Rivas et al., 2001). Most PEL lines display a very small
subpopulation of cells that stain for markers of lytic reactivation
such as ORF50, ORF59, and K8.1 (Katano et al., 2000b). Although
KSHV-encoded vIL-6 is thought as a lytic protein, vIL-6 is detected
more frequently in PEL cells than other lytic proteins. It has been
demonstrated that vIL-6 is a multifunctional protein; vIL-6 can
bind to IL-6 receptor gp130 in the absence of another subunit of
IL-6 receptor, gp80, suggesting vIL-6 can induce cytokine signals
in a broader range of cell types (Chatterjee et al., 2002). The signal
from gp130 often secretes human IL-6 itself, raising the possibility
of an autocrine loop. vIL-6 also induces VEGF expression, result-
ing in an indirect proliferation effect on PEL cells (Aoki et al.,
1999).
MULTICENTRIC CASTLEMAN’S DISEASE
Multicentric Castleman’s disease is characterized by plasmacytic
lymphoadenopathy with polyclonal hyperimmunoglobulinemia
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and high levels of IL-6 in the serum. Histologically, follicular
hyperplasia with proliferation of plasma cells and hyaline vascular
alterations are observed in the lymph nodes (Figure 1F). Two dis-
tinct histopathologic subtypes have been reported; the hyaline vas-
cular type (HV type) and the plasma cell type (PC-type). The HV
type is characterized by enlarged lymphoid follicles,hyalinized ger-
minal centerswithin an expandedmantle zone, and a highly vascu-
larized interfollicular area. In contrast, in the PC-type, remarkable
inﬁltration of plasma cells is observed in the interfollicular area.
Among these mantle zone cells, there are variable numbers of the
larger cells, which are approximately twice the size of mantle zone
lymphocytes. These cells are characterized by a moderate amount
of amphophilic cytoplasm and a large vesicular nucleus containing
one or sometimes two prominent nucleoli. These cells have been
called plasmablasts, although they frequently have immunoblas-
tic features (Dupin et al., 2000). The plasmablasts are also found
in the interfollicular area of PC-type MCD frequently. In some,
but not all cases of MCD, KSHV is detected (Soulier et al., 1995).
Using PCR, KSHV is frequently detected in tissues obtained from
patients with MCD associated with HIV infection, but is very rare
in MCD cases without HIV infection (Suda et al., 2001). KSHV
was also detected with high frequency in MCD complicated with
polyneuropathy, organomegaly, endocrinopathy, M protein, and
skin changes (POEMS) syndrome (Belec et al., 1999). Immuno-
histochemistry for LANA-1 revealed that KSHV-infected cells are
localized in the mantle zone of lymphoid follicles (Figure 1G).
Besides LANA-1, other KSHV-encoded lytic proteins such as vIL-
6, K8, and K8.1 are also detected in these cells, suggesting KSHV+
MCD is associated with KSHV-lytic infection (Dupin et al., 1999;
Katano et al., 2000b). The KSHV-encoded vIL-6 plays a role in the
proliferation of plasma cells, and is also detected in patients’ sera
at high levels, suggesting high levels of vIL-6 are associated with
MCD pathogenesis (Parravicini et al., 1997). High levels of KSHV
DNA are also detected in the serum, which can be a marker of
progressive MCD.
LARGE B-CELL LYMPHOMA ARISING IN KSHV-ASSOCIATED MCD
Large B-cell lymphoma arising in KSHV-associated MCD is char-
acterized by a monoclonal proliferation of KSHV-infected lym-
phoid cells resembling plasmablasts expressing IgM, arising in the
setting of MCD (Dupin et al., 2000; Oksenhendler et al., 2002).
The small conﬂuent sheets of LANA-1+ plasmablasts are seen in
the interfollicular zone of KSHV-associated MCD. This type of
lymphoma occurs in the lymph node or spleen with generalized
lymphadenitis and/or massive splenomegaly. Plasmablasts show
stippled nuclear staining for LANA-1 and cytoplasmic staining for
vIL-6, and strongly express cIgM with λ light-chain restriction.
CONCLUSION
Since the discovery of KSHV, 16 years have passed. During the
period, some useful diagnostic tools have been developed for
pathological examination. Anti-LANA-1 antibody is the most
powerful tool for diagnosis of pathological samples of KSHV infec-
tion. LANA-1 expression is speciﬁc to KSHV infection, because
all KSHV-infected cells express LANA-1. Real-time PCR is also a
powerful tool for diagnosis. Thus, it is not difﬁcult to diagnose
KSHV infection in pathological samples. On the other hand, the
pathogenesis, and especially the oncogenesis, of KSHV remain
unknown. Although many KSHV-encoded proteins have been
characterized and their in vitro functions revealed, it is still not
clear if KSHV can fully transform or immortalize endothelial
cells. It has been shown that LANA-1 plays a central role in KSHV
pathogenesis. However, LANA-1 is not enough for KSHV oncoge-
nesis. KSHV-encoded non-transforming proteins may collaborate
to establish and maintain appropriate environment for KSHV-
infected cells. Further studies should reveal the mechanism of the
collaboration by KSHV-encoded proteins.
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